Top Page
Xilio Therapeutics
(NASDAQ:XLO)
Xilio Therapeutics (XLO) vs. SPDR S&P 500 ETF (SPY)
Xilio Therapeutics Business Overview & Revenue Model
Xilio Therapeutics Financial Statement Overview
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 43.77M | 6.34M | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 6.34M | 0.00 | 0.00 | -1.50M |
| EBITDA | -41.98M | -58.00M | -77.23M | -87.30M | -73.70M |
| Net Income | 0.00 | -58.24M | -76.40M | -88.22M | -75.80M |
Balance Sheet | |||||
| Total Assets | 154.69M | 71.08M | 60.93M | 139.16M | 221.60M |
| Cash, Cash Equivalents and Short-Term Investments | 137.53M | 55.29M | 44.70M | 120.39M | 198.05M |
| Total Debt | 6.95M | 8.14M | 11.46M | 19.94M | 20.74M |
| Total Liabilities | 119.41M | 53.48M | 24.10M | 33.52M | 36.17M |
| Stockholders Equity | 35.27M | 17.60M | 36.83M | 105.65M | 185.43M |
Cash Flow | |||||
| Free Cash Flow | -5.51M | -18.41M | -69.11M | -77.59M | -81.85M |
| Operating Cash Flow | -4.99M | -18.38M | -68.62M | -75.72M | -80.75M |
| Investing Cash Flow | -518.00K | -36.00K | -486.00K | -1.87M | -1.10M |
| Financing Cash Flow | 87.78M | 29.20M | -6.55M | -69.00K | 260.67M |
Xilio Therapeutics Technical Analysis
Xilio Therapeutics Risk Analysis
Xilio Therapeutics Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | $320.81M | -3.77 | -110.72% | ― | ― | 77.08% | |
53 Neutral | $164.92M | -1.05 | ― | ― | ― | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $25.05M | -2.82 | -125.98% | ― | ― | 1.18% | |
49 Neutral | $41.24M | -1.86 | -857.86% | ― | 588.40% | 61.76% | |
48 Neutral | $370.04M | -2.14 | -115.27% | ― | 2925.73% | -294.29% | |
42 Neutral | $84.76M | -7.23 | ― | ― | ― | ― |
Xilio Therapeutics Corporate Events
On March 12, 2026, Xilio Therapeutics announced that it would implement a 1-for-14 reverse stock split of its common shares, effective at 5:00 p.m. Eastern Time on March 13, 2026. The move, approved by stockholders at a special meeting on February 23, 2026, is intended to raise the company’s per-share price and help it regain compliance with the Nasdaq Capital Market’s minimum bid price requirements.
Following the reverse split, Xilio’s common stock is expected to begin trading on a split-adjusted basis on March 16, 2026 under the ticker XLO with a new CUSIP, reducing outstanding shares from about 73.5 million to roughly 5.2 million. The action leaves the number of authorized shares and par value unchanged, adjusts related warrants and equity awards, and provides cash in lieu of fractional shares, affecting the capital structure and share count for existing investors without altering underlying ownership proportionally.
The most recent analyst rating on (XLO) stock is a Hold with a $0.59 price target. To see the full list of analyst forecasts on Xilio Therapeutics stock, see the XLO Stock Forecast page.
On March 9, 2026, Xilio Therapeutics posted an updated corporate investor presentation outlining its strategy to leverage clinically validated masking technology to develop tumor-selective immuno-oncology candidates, including vilastobart, efarindodekin alfa and next-generation bispecific and multi-specific T cell engager programs. The company highlighted key development timelines for its pipeline, including an IND submission for XTX501 in mid-2026 and initial Phase 1 data in the second half of 2027, as well as anticipated milestone and option payments from AbbVie and Gilead, which, together with $137.5 million in estimated year-end 2025 cash and a recent $40 million follow-on offering, are expected to support continued advancement of its portfolio and strengthen its financial and competitive position in the I-O space.
The most recent analyst rating on (XLO) stock is a Hold with a $0.59 price target. To see the full list of analyst forecasts on Xilio Therapeutics stock, see the XLO Stock Forecast page.
On February 23, 2026, Xilio Therapeutics, Inc. held a special meeting of stockholders at which investors approved an amendment to the company’s restated certificate of incorporation to enable a reverse stock split of its common shares at a ratio to be set between 1-for-2 and 1-for-30 by the board of directors. This approval gives the board flexibility to adjust the share count and potentially support the company’s stock price without returning to shareholders for another vote, and stockholders also backed a proposal to adjourn the meeting if needed for additional proxy solicitation related to the reverse split.
The most recent analyst rating on (XLO) stock is a Hold with a $0.59 price target. To see the full list of analyst forecasts on Xilio Therapeutics stock, see the XLO Stock Forecast page.
On February 11, 2026, Xilio Therapeutics announced the pricing of an underwritten offering of pre-funded warrants to purchase 74,780,300 shares of common stock at $0.5349 per warrant, each exercisable at $0.0001 per share. The transaction, led by Leerink Partners as sole bookrunner, is expected to close on or about February 13, 2026, subject to customary closing conditions and exercise limitations that cap individual holders’ beneficial ownership.
The offering is expected to generate approximately $40 million in gross proceeds, or about $37.1 million in net proceeds after underwriting discounts, commissions and expenses, with Xilio planning to use the funds to advance its cancer drug pipeline and for general corporate purposes. Participation by existing backers Coastlands Capital and major healthcare investors including Gilead Sciences, OrbiMed and Perceptive Advisors underscores continued institutional support and provides Xilio with additional runway to execute its clinical strategy in a challenging biotech funding environment.
The most recent analyst rating on (XLO) stock is a Hold with a $0.59 price target. To see the full list of analyst forecasts on Xilio Therapeutics stock, see the XLO Stock Forecast page.
On January 8, 2026, Xilio Therapeutics reported a series of corporate and pipeline updates, including the receipt of $35.8 million in gross proceeds in the fourth quarter of 2025 from the exercise of Series B warrants, which extended its estimated cash runway into the second quarter of 2027 and brought preliminary year-end 2025 cash and cash equivalents to about $137.5 million. The company also achieved a development milestone in its masked antibody-based immunotherapy program under its AbbVie collaboration, nominated a development candidate for a wholly owned masked T cell engager targeting CLDN18.2—relevant for gastric, pancreatic, esophageal and lung cancers—and laid out a roadmap of key clinical and regulatory milestones through 2027, including an IND filing and initial Phase 1 data for XTX501, candidate nomination for a STEAP1 program, and advancing at least two masked T cell engager programs into IND-enabling studies. Governance changes were highlighted with the appointment of longtime director and experienced biotech finance executive Sara M. Bonstein as chair of the board following the January 6, 2026 retirement of former chair Paul Clancy, a transition presented as orderly and non-contentious that is expected to reinforce financial and strategic oversight as Xilio seeks to translate its masking platform into value-generating clinical assets and partnership-driven growth.
The most recent analyst rating on (XLO) stock is a Hold with a $0.62 price target. To see the full list of analyst forecasts on Xilio Therapeutics stock, see the XLO Stock Forecast page.
In June 2025, Xilio Therapeutics issued 66,676,000 Series B warrants and 66,676,000 Series C warrants as part of a follow-on public offering. By December 31, 2025, 48,207,815 Series B warrants had been exercised, resulting in the issuance of 8,202,815 shares of common stock and 40,005,000 prefunded warrants, and generating $35.8 million in gross proceeds before transaction costs. As a result of the warrant activity and prior prefunded warrant exercises, Xilio had 67,540,930 shares of common stock outstanding as of January 2, 2026, while 48,207,815 Series C warrants remained outstanding and 18,468,185 Series C warrants expired in line with the lapse of unexercised Series B warrants. The company indicated that, based on its current operating plans and the net proceeds from the Series B warrant exercises, its cash and cash equivalents are expected to fund operating expenses and capital expenditures into the second quarter of 2027, strengthening its near- to medium-term financial runway and providing additional visibility for investors and other stakeholders.
The most recent analyst rating on (XLO) stock is a Hold with a $0.62 price target. To see the full list of analyst forecasts on Xilio Therapeutics stock, see the XLO Stock Forecast page.